CONTESTING RECORD PROCEDURES:
Individuals wishing to contest or request an amendment to their records in this system of records must submit their request in writing to the FDIC FOIA & Privacy Act Group, 550 17th Street NW, Washington, DC 20429, or email efoia@fdic.gov. Requests must specify the information being contested, the reasons for contesting it, and the proposed amendment to such information in accordance with FDIC regulations at 12 CFR part 310.

NOTIFICATION PROCEDURES:
Individuals wishing to know whether this system contains information about them must submit their request in writing to the FDIC FOIA & Privacy Act Group, 550 17th Street NW, Washington, DC 20429, or email efoia@fdic.gov. Requests must include full name, address, and verification of identity in accordance with FDIC regulations at 12 CFR part 310.

EXCEPTIONS PROMULGATED FOR THE SYSTEM:
None.

HISTORY:
None.

Federal Deposit Insurance Corporation.
Dated at Washington, DC, on May 6, 2022.

James P. Sheesley,
Assistant Executive Secretary.
[FR Doc. 2022–10427 Filed 5–13–22; 8:45 am]
BILLING CODE 6714–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/request.htm. Interested persons may express their views in writing on the

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number CDC–2022–0066, NIOSH–346]

Draft National Institute for Occupational Safety and Health (NIOSH) Healthcare Personal Protective Technology (PPT) Targets for 2020 to 2030; Request for Comment

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Request for information and comment.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) in the Centers for Disease Control and Prevention (CDC), an Operating Division of the Department of Health and Human Services (HHS), announces the availability of a draft document entitled DRAFT NIOSH Healthcare Personal Protective Technology (PPT) Targets for 2020 to 2030 (Draft PPT Targets) now available for public comment.

DATES: Electronic or written comments must be received by July 15, 2022.

ADDRESSES: You may submit comments, identified by CDC–2022–0066 and docket number NIOSH–346, by either of the following methods:
• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.
• Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998.

INSTRUCTIONS: All information received in response to this notice must include the agency name and docket number (CDC–2022–0066; NIOSH–346). All relevant comments, including any personal information provided, will be posted without change to https://www.regulations.gov. Do not submit comments by email. CDC does not accept comments by email. For access to the docket to read background documents or comments received, go to https://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Dr. Susan M. Moore, NIOSH NPPTL, Building 141, 626 Cochran’s Mill Road, Pittsburgh, PA 15236; Telephone: 412–366–6111.

SUPPLEMENTARY INFORMATION: Reflecting on the nation’s past decade of experiences with infectious diseases (e.g., influenza, Ebola virus disease, and coronavirus disease) and non-infectious hazards (e.g., antineoplastic and other hazardous drugs), the National Institute for Occupational Safety and Health (NIOSH) recognizes a growing need for its unique capabilities related to PPT research, development, performance standards and test methods, and conformity assessment. In response to this growing need, NIOSH established DRAFT Healthcare PPT Targets for 2020 to 2030.

Background: The health and welfare of 18 million U.S. healthcare personnel (HCP) is an important priority for NIOSH and CDC. NIOSH’s mission is to protect the U.S. workforce from injury and illness via scientific research, practice interventions, and collaborative partnerships. While infection prevention and control efforts favor the role of engineering and administrative measures over PPT, PPT plays an important role in preventing transmission of infectious diseases. PPT includes personal protective equipment (PPE) worn by individuals (e.g., respirators; protective clothing; gloves, eye, and hearing protection; and hard hats) and technical methods (e.g.,
fit testing methods), processes, techniques, tools, and materials that support the development and use of PPE worn by individuals.

In 2006, the NIOSH Personal Protective Technology Laboratory (NPTL) began an initiative to develop and execute a comprehensive strategic approach to HCP protection. The resulting NIOSH Healthcare PPT Action Plan focused resources on and raised awareness about the PPT needs of HCP during a potential influenza pandemic. NIOSH undertook a research agenda to advance clinical practices, drive performance standards development, and inform regulation. In addition, NIOSH carried out an information dissemination program to apprise healthcare organizations and HCP about the roles and importance of PPE in protecting themselves. The Action Plan has been updated several times since its inception. The most recent plan (2013–18) focused on PPE used to reduce exposures to viral respiratory pathogens, including the influenza virus.

Reflecting on the nation’s past decade of experiences with infectious diseases (e.g., influenza, Ebola, and coronavirus) and non-infectious hazards (e.g., antineoplastic and other hazardous drugs), NIOSH recognizes a growing need for its unique capabilities related to PPT research, development, performance standards development, and conformity assessment. To respond to this growing need, NIOSH developed DRAFT NIOSH Healthcare PPT Targets for 2020 to 2030 (Draft PPT Targets), which have informed NIOSH’s PPT efforts since 2020. The public health response to the COVID–19 pandemic has delayed NIOSH’s efforts to obtain public input on the PPT Targets; NIOSH will finalize the PPT Targets after receipt of the requested public input. To view the Draft PPT Targets, please visit https://www.cdc.gov/niosh/npptl/DraftHealthcarePPT.html.

Information Needs: Additional data and information are needed to assist with finalizing the Draft PPT Targets. Interested persons or organizations are invited to submit applicable materials, including published and unpublished reports and research findings, that NIOSH may consider to:

- Explore additional or alternative technical approaches; and
- Explore additional knowledge gaps requiring support until 2030.

Disclaimer: This notice is intended for planning purposes; it does not constitute a formal announcement for comprehensive applications. In accordance with Federal Acquisition Regulation 48 CFR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding award. NIOSH will not provide reimbursement for costs incurred in commenting on this notice. NIOSH will not respond to individual public comments or publish publicly a compendium of responses. An informational submission in response to this notice does not create any commitment by or on behalf of CDC or HHS to develop or pursue any program or ideas discussed.

John J. Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2022–10413 Filed 5–13–22; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2019–N–2854]

Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Tobacco Product Applications and Recordkeeping Requirements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicit comments on “Premarket Tobacco Product Applications and Recordkeeping Requirements.”

DATES: Submit either electronic or written comments on the collection of information by July 15, 2022.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before July 15, 2022. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 15, 2022. Comments received by mail/hand delivery/courier for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2019–N–2854 for “Premarket Tobacco Product Applications and Recordkeeping Requirements.”

Received comments, those filed in a